Inhibrx Biosciences, Inc. financial data

Symbol
INBX on Nasdaq
Location
La Jolla, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 464% %
Debt-to-equity 144% %
Return On Equity -186% % -113%
Return On Assets -76% %
Operating Margin -11002% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 14,543,738 shares 0.47%
Common Stock, Shares, Outstanding 14,498,093 shares 0.15%
Entity Public Float $169,400,000 USD
Common Stock, Value, Issued $1,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 15,478,000 shares 0.06%
Weighted Average Number of Shares Outstanding, Diluted 15,478,000 shares 0.06%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $1,400,000 USD
Research and Development Expense $121,046,000 USD -27%
General and Administrative Expense $34,384,000 USD -33%
Operating Income (Loss) $154,030,000 USD 28%
Nonoperating Income (Expense) $1,054,000 USD -149%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $35,256,000 USD 20%
Income Tax Expense (Benefit) $2,000 USD
Net Income (Loss) Attributable to Parent $155,086,000 USD -109%
Earnings Per Share, Basic -11 USD/shares 20%
Earnings Per Share, Diluted -11 USD/shares 20%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $153,088,000 USD -22%
Other Assets, Current $410,000 USD -45%
Assets, Current $161,423,000 USD -22%
Property, Plant and Equipment, Net $4,306,000 USD -37%
Operating Lease, Right-of-Use Asset $6,004,000 USD 294%
Other Assets, Noncurrent $5,738,000 USD -15%
Assets $177,471,000 USD -20%
Accounts Payable, Current $6,773,000 USD -45%
Employee-related Liabilities, Current $4,835,000 USD -25%
Accrued Liabilities, Current $26,963,000 USD -9.8%
Liabilities, Current $35,983,000 USD -18%
Operating Lease, Liability, Noncurrent $4,741,000 USD
Liabilities $140,641,000 USD 219%
Retained Earnings (Accumulated Deficit) $213,353,000 USD -266%
Stockholders' Equity Attributable to Parent $36,830,000 USD -79%
Liabilities and Equity $177,471,000 USD -20%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $35,895,000 USD 43%
Net Cash Provided by (Used in) Financing Activities $99,840,000 USD 158%
Net Cash Provided by (Used in) Investing Activities $21,000 USD 98%
Common Stock, Shares Authorized 120,000,000 shares 0%
Common Stock, Shares, Issued 14,498,093 shares 0.15%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $63,924,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $153,088,000 USD -22%
Interest Paid, Excluding Capitalized Interest, Operating Activities $1,299,000 USD -81%
Deferred Tax Assets, Valuation Allowance $21,789,000 USD -85%
Deferred Tax Assets, Gross $23,983,000 USD -84%
Operating Lease, Liability $6,988,000 USD 281%
Payments to Acquire Property, Plant, and Equipment $21,000 USD -98%
Lessee, Operating Lease, Liability, to be Paid $7,991,000 USD 322%
Property, Plant and Equipment, Gross $14,881,000 USD -1.4%
Operating Lease, Liability, Current $2,247,000 USD 22%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,941,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $2,855,000 USD 151%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 24%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,003,000 USD 1660%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,492,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $4,726,000 USD -93%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 15,000,000 shares 0%
Unrecognized Tax Benefits $0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,492,000 USD
Additional Paid in Capital $250,182,000 USD 5.7%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $2,609,000 USD -23%
Deferred Tax Assets, Net of Valuation Allowance $2,194,000 USD 233%
Share-based Payment Arrangement, Expense $1,800,000 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%